ForCast Orthopedics develops targeted antibiotic therapies to treat periprosthetic joint infection (PJI), a serious complication of joint replacement surgery. By leveraging a specialized infusion platform that delivers antibiotics directly to the infection site, the company aims to overcome biofilm resistance and improve outcomes for joint replacement patients. Its pipeline includes FDA‑designated programs such as FC002, focused on modernizing care for complex orthopedic infections.
Funding
$3.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Periprosthetic joint infection (PJI) occurs after joint replacement surgery and is difficult to treat because bacteria form biofilms on the prosthetic surface, making systemic antibiotics ineffective and leading to low cure rates, high costs, and risk of limb loss.
Solution
ForCast Orthopedics has created a targeted antibiotic therapy that is delivered locally to the infected joint using KORU Medical’s FreedomEDGE® infusion system. The platform administers high concentrations of antibiotic directly to the prosthetic surface, penetrating biofilm and eradicating bacteria while minimizing systemic exposure. The treatment is automated and integrates with existing surgical workflows, allowing clinicians to apply the therapy intra‑operatively or during revision procedures. By focusing drug delivery to the infection site, the approach aims to improve patient outcomes, reduce the need for prolonged systemic antibiotic courses, and lower overall treatment costs.
Target Audience
Primary customers are orthopedic surgeons and hospital systems that perform joint replacement and revision surgeries and need effective solutions for treating PJI.
Features
- Proprietary antibiotic formulation optimized for biofilm penetration
- Integration with FreedomEDGE® infusion system for precise, localized delivery
- Automated dosing protocol that aligns with standard surgical procedures
- Reduced systemic antibiotic exposure, lowering side‑effect risk
- Designed for use in both primary revision and staged infection surgeries